Diabetic Eye Disease Epidemiology Forecast 2026-2035

Diabetic eye disease, a leading cause of vision impairment, is closely linked to the growing global diabetes burden. According to David R. Owens et al., 2025, diabetes cases are projected to rise from over 500 million today (≈6% prevalence) to more than 1 billion (≈10%) by 2050, with over 90% being type 2. Additionally, a pooled analysis of 59 population-based studies estimates that global cases of diabetic retinopathy will increase from 103.12 million to 160.50 million, while sight-threatening retinopathy may grow from 28.54 million to 44.82 million by 2045. According to the diabetic eye disease epidemiology forecast, the rising prevalence of diabetes is expected to significantly elevate the global burden of diabetic eye disease in the coming decades.

Diabetic Eye Disease Epidemiology Forecast Report Coverage

The analyst's “Diabetic Eye Disease Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of diabetic eye disease. It projects the future incidence and prevalence rates of diabetic eye disease cases across various populations. The study covers age, gender, and type as major determinants of the diabetic eye disease population. The report highlights patterns in the prevalence of diabetic eye disease over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of diabetic eye disease in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Diabetic Eye Disease Understanding: Disease Overview

Diabetic eye disease refers to a cluster of diabetes-related ocular complications that can lead to visual impairment and blindness if left untreated. The condition primarily encompasses diabetic retinopathy (DR), diabetic macular edema (DME), diabetic cataracts, and diabetic glaucoma. Diabetic retinopathy, caused by prolonged hyperglycemia damaging retinal microvasculature, is the leading cause of preventable blindness among working-age adults globally. It is classified into non-proliferative diabetic retinopathy (NPDR) and the more advanced proliferative diabetic retinopathy (PDR). Both type 1 and type 2 diabetes patients are at risk, with duration of diabetes and degree of glycemic control being the primary determinants of progression. Key risk factors include hypertension, hyperlipidemia, obesity, pregnancy, and nephropathy. The condition is often asymptomatic in early stages, making regular screening essential for timely intervention.

Diabetic Eye Disease Epidemiology Perspective

The diabetic eye disease epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for the diabetic eye disease epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for diabetic eye disease and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Zhen Ling Teo et al., 2021, the global prevalence of diabetic retinopathy among individuals with diabetes was 22.27% in 2020, while vision-threatening diabetic retinopathy reached 6.17% and clinically significant macular edema accounted for 4.07%, indicating a substantial worldwide disease burden.
• As per Zhen Ling Teo et al., 2021, approximately 103.12 million adults were living with diabetic retinopathy globally in 2020, and the number is projected to rise to 160.50 million by 2045, reflecting increasing diabetes prevalence and expanding patient populations.
• According to Zornitsa Zlatarova et al., 2024, diabetic retinopathy primarily affects working-age adults between 20 and 74 years, with prevalence rising significantly with increasing age and longer diabetes duration, highlighting age-related progression of retinal complications.
• As per Heba AlSawahli et al., 2021, gender differences exist in disease burden, with women showing slightly higher prevalence of diabetes and diabetic retinopathy, such as 23.8% diabetes prevalence in females compared with 18.9% in males in surveyed populations.
• According to Heba AlSawahli et al., 2021, diabetic retinopathy contributed to moderate to severe visual impairment in about 2.6 million people globally, emphasizing its role as a leading cause of preventable vision loss among adults with diabetes.

Country-wise Diabetic Eye Disease Epidemiology

The diabetic eye disease epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of diabetic eye disease demonstrates substantial regional variation but reflects the increasing global diabetes burden. According to Min Seok Kim et al., 2025, diabetic retinopathy prevalence among individuals with diabetes is 26.43% in the United States, including 5.06% with vision-threatening disease, while Europe reports a prevalence of about 25.7%, encompassing countries such as the United Kingdom, Germany, France, Spain, and Italy. In Japan, the prevalence among diabetic patients is 23.6%, as per the same study. Additionally, according to Penn Medicine (University of Pennsylvania) analysis, the proportion of diabetes-related retinal disease in the United States increased from 10.8% in 2014 to 20.8% in 2021, with incidence rising from 17.7 to 32.2 cases per 1,000 person-years between 2013 and 2022. According to Tien Yin Wong et al., 2023, in India, rising diabetes prevalence is driving increasing diabetic retinopathy burden, which affects 30-40% of individuals with diabetes globally.

Diabetic Eye Disease: Treatment Overview

Treatment of diabetic eye disease spans a continuum from preventive glycemic and blood pressure control to pharmacological and surgical interventions for advanced diseases. Anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections, including agents such as ranibizumab, bevacizumab, and aflibercept, represent the standard of care for diabetic macular edema and proliferative diabetic retinopathy. Laser photocoagulation, historically the mainstay of DR treatment, continues to be employed for peripheral retinal ablation. Intraocular corticosteroid implants such as Ozurdex and Iluvien provide sustained drug delivery for patients unresponsive to anti-VEGF therapy. Vitrectomy is indicated for advanced complications, including tractional retinal detachment and non-resolving vitreous hemorrhage. Emerging approaches include artificial intelligence-assisted screening platforms, with companies such as Google licensing AI-based DR detection models to healthcare partners in Asia and other regions.

Key Questions Answered

• What are the key findings of diabetic eye disease epidemiology in the 8 major markets?
• What will be the total number of patients with diabetic eye disease across the 8 major markets during the forecast period?
• What was the country-wise diabetic eye disease epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of diabetic eye disease patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of diabetic eye disease during the forecast period of 2026-2035?
• What are the currently available treatments for diabetic eye disease?
• What are the disease risks, signs, symptoms, and unmet needs of diabetic eye disease?

Scope of the Diabetic Eye Disease Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of diabetic eye disease based on several factors.
• Diabetic Eye Disease Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The diabetic eye disease report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.